Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density. / Eriksson, Robert; Broberg, Brian V.; Ishoy, Pelle L.; Bak, Nikolaj; Andersen, Ulrik B.; Jorgensen, Niklas R.; Knop, Filip K.; Ebdrup, Bjørn H.

In: Frontiers in Psychiatry, Vol. 9, 781, 2019.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Eriksson, R, Broberg, BV, Ishoy, PL, Bak, N, Andersen, UB, Jorgensen, NR, Knop, FK & Ebdrup, BH 2019, 'Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density', Frontiers in Psychiatry, vol. 9, 781. https://doi.org/10.3389/fpsyt.2018.00781

APA

Eriksson, R., Broberg, B. V., Ishoy, P. L., Bak, N., Andersen, U. B., Jorgensen, N. R., ... Ebdrup, B. H. (2019). Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density. Frontiers in Psychiatry, 9, [781]. https://doi.org/10.3389/fpsyt.2018.00781

Vancouver

Eriksson R, Broberg BV, Ishoy PL, Bak N, Andersen UB, Jorgensen NR et al. Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density. Frontiers in Psychiatry. 2019;9. 781. https://doi.org/10.3389/fpsyt.2018.00781

Author

Eriksson, Robert ; Broberg, Brian V. ; Ishoy, Pelle L. ; Bak, Nikolaj ; Andersen, Ulrik B. ; Jorgensen, Niklas R. ; Knop, Filip K. ; Ebdrup, Bjørn H. / Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density. In: Frontiers in Psychiatry. 2019 ; Vol. 9.

Bibtex

@article{18be0390446940a3a248f7f01adbe867,
title = "Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density",
keywords = "exenatide, procollagen type I N-terminal propeptide (PINP), C-terminal cross-linking telopeptide of type I collagen (CTX), bone mineral density, randomized controlled trial",
author = "Robert Eriksson and Broberg, {Brian V.} and Ishoy, {Pelle L.} and Nikolaj Bak and Andersen, {Ulrik B.} and Jorgensen, {Niklas R.} and Knop, {Filip K.} and Ebdrup, {Bj{\o}rn H.}",
year = "2019",
doi = "10.3389/fpsyt.2018.00781",
language = "English",
volume = "9",
journal = "Frontiers in Psychiatry",
issn = "1664-0640",
publisher = "Frontiers Research Foundation",

}

RIS

TY - JOUR

T1 - Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density

AU - Eriksson, Robert

AU - Broberg, Brian V.

AU - Ishoy, Pelle L.

AU - Bak, Nikolaj

AU - Andersen, Ulrik B.

AU - Jorgensen, Niklas R.

AU - Knop, Filip K.

AU - Ebdrup, Bjørn H.

PY - 2019

Y1 - 2019

KW - exenatide

KW - procollagen type I N-terminal propeptide (PINP)

KW - C-terminal cross-linking telopeptide of type I collagen (CTX)

KW - bone mineral density

KW - randomized controlled trial

U2 - 10.3389/fpsyt.2018.00781

DO - 10.3389/fpsyt.2018.00781

M3 - Journal article

C2 - 30745885

VL - 9

JO - Frontiers in Psychiatry

JF - Frontiers in Psychiatry

SN - 1664-0640

M1 - 781

ER -

ID: 213322322